Wuhan Keqian Biology Co.,Ltd (688526.SS)
CNY 15.75
(-1.69%)
CNY 15.75
(-1.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 833.59 Million CNY | -6.51% |
| 2022 | 891.62 Million CNY | 56.04% |
| 2021 | 571.41 Million CNY | 42.0% |
| 2020 | 402.4 Million CNY | 59.38% |
| 2019 | 252.47 Million CNY | -28.58% |
| 2018 | 353.51 Million CNY | 36.57% |
| 2017 | 258.86 Million CNY | 44.61% |
| 2016 | 179 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 714.7 Million CNY | -14.26% |
| 2024 Q3 | 573.29 Million CNY | -10.01% |
| 2024 Q2 | 637.02 Million CNY | -10.87% |
| 2023 Q1 | 1.03 Billion CNY | 16.39% |
| 2023 FY | 833.59 Million CNY | -6.51% |
| 2023 Q2 | 882.1 Million CNY | -15.0% |
| 2023 Q4 | 833.59 Million CNY | -14.07% |
| 2023 Q3 | 970.12 Million CNY | 9.98% |
| 2022 Q4 | 891.62 Million CNY | 19.25% |
| 2022 Q3 | 747.67 Million CNY | 17.75% |
| 2022 Q2 | 634.98 Million CNY | 11.41% |
| 2022 Q1 | 569.92 Million CNY | -0.26% |
| 2022 FY | 891.62 Million CNY | 56.04% |
| 2021 Q4 | 571.41 Million CNY | -16.02% |
| 2021 Q3 | 680.39 Million CNY | 45.73% |
| 2021 Q2 | 466.88 Million CNY | -3.21% |
| 2021 Q1 | 482.35 Million CNY | 19.87% |
| 2021 FY | 571.41 Million CNY | 42.0% |
| 2020 Q3 | 443.86 Million CNY | 53.94% |
| 2020 FY | 402.4 Million CNY | 59.38% |
| 2020 Q4 | 402.4 Million CNY | -9.34% |
| 2020 Q2 | 288.32 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 252.47 Million CNY | 0.0% |
| 2019 Q2 | 199.15 Million CNY | 0.0% |
| 2019 FY | 252.47 Million CNY | -28.58% |
| 2018 FY | 353.51 Million CNY | 36.57% |
| 2017 FY | 258.86 Million CNY | 44.61% |
| 2016 FY | 179 Million CNY | 0.0% |